Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2005

View Archived Issues

Peregrine signs licensing agreement with Medarex for vascular targeting agents

New preclinical data support use of OXI-4503 in cancer

Inyx to acquire Celltech Manufacturing Services from UCB

EncorePharma receives phase I SBIR grant for Huntington's disease research

Acambis on track to begin phase III trials of ChimeriVax-JE by year-end

AL-208 enters phase I trials for MCI associated with CABG

Sunesis selects Aurora kinase candidate for preclinical development

New study evaluates Cotara for glioblastoma multiforme

Advaxis completes preclinical toxicology studies for Lovaxin C

SCOLR Pharma completes pilot bioavailability testing of CDT-raloxifene

Enrollment completed in phase II study of ozarelix for prostate cancer

Discovery receives FDA notification regarding Surfaxin response letter

Positive findings in open-label study of Prestara

Preclinical profile of AMG-8163 for the treatment of pain

Preclinical summary on ONO-2921, a Cav2.2 blocker for pain

Actoplus Met approved for type 2 diabetes

sBLA filed for Erbitux for head and neck cancer

New data on Remune presented

CHIR-258 active against acute myelogenous leukemia cells in vitro and in vivo

Novel BK-1 antagonist with high selectivity and good PK profile

TAK-242 subject of presentation at ACS meeting

Maraviroc reported safe and effective in HIV infection

EGIS-11229: A novel noncompetitive AMPA receptor antagonist

Case report: Reboxetine induces weight loss

Recent patents describe novel antiinfective agents

New potential treatments for obesity emerge from pharmaceutical R&D

Novel agents for thrombotic disorders imparted by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...